Recombinant Human T-Cell Lymphotropic Virus Type I&II chimeric antigen

HTLV-1 is a human retrovirus responsible for adult T-cell leukemia (ATL) and certain other clinical disorders. The viral Tax oncoprotein plays a central role in HTLV-1 pathogenicity, mainly due to its capacity of inducing the transcriptional activity of various transcriptional factors like NF boxed times B. Eucalyptus camaldulensis(Ec) is considered as a traditional medicinal plant with valuable therapeutic effects. Here we evaluated the activity of its ethanolic leave extract on different Tax activities by testing its influence on Tax-induced activity of NF boxed times B and HTLV-1 LTR in Jurkat cells. Our results showed thatEcinhibited Tax induced activation of NF boxed times B -, SRF- dependent promoters and HTLV-1 LTR.Ec extract has no effect on the binding of Tax to NF boxed times B while it strongly prevented the degradation of I kappa B alpha induced by Tax probably as a result of preventing the link between Tax and IKK gamma. In addition, increasing the cellular level of P-TEFb-cyclinT1 significantly reduced the inhibitory effect of Econ Tax activities, probably by preventing the interaction between Tax and P-TEFb-cyclin T1. The 40%-MeOH fraction of this extract, which is rich with polyphenols, offered the highest inhibitory effect against Tax activities. Further studies are required for the isolation and identification of active component/s in this extract which may be developed in the future as preventive/curing drugs for HTLV-1 related diseases.

Adult T cell leukemia-lymphoma (ATL) is a mature T cell malignancy associated with human T cell leukemia virus type I (HTLV-1), a retrovirus that is endemic in southwestern Japan. Because of population migration, cases of An are expected to increase in nonendemic areas. Here, to clarify the outcomes of patients with An in the nonendemic metropolitan area of Osaka, we retrospectively analyzed data from the population-based Osaka Cancer Registry from 2010 to 2015. This analysis included 91 patients age <= 70 years who received chemotherapy for ATL. With a median follow-up of 988 days in surviving patients, the probability of 2-year overall survival (OS) was 21.9% (95% confidence interval [CI], 14.1% to 30.9%) and the median OS was 9.8 months (95% CI, 7.3 to 13.5 months). The probability of 2-year OS was 22.2% in the nontransplant group (n = 63) and 21.4% in the transplant group (n = 28), without a statistically significant difference between the 2 groups. Allogeneic transplantation was not a favorable prognostic factor in patients with ATL in propensity score-adjusted analysis (P = .86, log-rank test). More clinical studies are needed to improve the clinical outcomes of patients with An in nonendemic areas. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.